Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.

@article{Genovese2007SafetyAE,
  title={Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.},
  author={Mark C Genovese and Philip J Mease and Glen T. D. Thomson and Alan J. Kivitz and Renee J Perdok and Mark A. Weinberg and John R Medich and Eric H. Sasso},
  journal={The Journal of rheumatology},
  year={2007},
  volume={34 5},
  pages={1040-50}
}
OBJECTIVE To demonstrate the safety and efficacy of adalimumab for the treatment of active psoriatic arthritis (PsA) in patients with an inadequate response to disease modifying antirheumatic drugs (DMARD). METHODS In a placebo controlled, double-blind, randomized, multicenter study, patients were treated for 12 weeks with subcutaneous injections of adalimumab 40 mg every other week (eow) or placebo, followed by a period of open-label treatment with adalimumab 40 mg eow. The primary efficacy… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 60 extracted citations

Similar Papers

Loading similar papers…